Sonablate Expands Leadership to Accelerate Growth in Incision-Free Prostate Care Solutions

Appointments support rising demand for HIFU and advance the 'precision sound medicine' platform across new clinical applications

Apr. 10, 2026 at 4:05am

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray image of a human prostate gland, glowing with an inner energy and surrounded by a dark, mysterious background, conceptually illustrating the precision and power of Sonablate's focused ultrasound technology.Sonablate's non-invasive HIFU technology uses targeted ultrasound energy to precisely treat prostate cancer while preserving patient quality of life.Charlotte Today

Sonablate, a global leader in focused ultrasound technologies, announced key additions to its leadership team as it scales 'precision sound medicine'—using targeted ultrasound energy to treat disease without surgery while preserving patient quality of life. The expanded leadership team will accelerate global adoption, strengthen clinical integration, and expand Sonablate's platform beyond prostate cancer and into additional therapeutic areas.

Why it matters

The appointments come as demand for non-invasive, focal therapies accelerate, with prostate cancer care shifting toward approaches that balance disease control with quality of life. Clinical data increasingly supports this transition, with studies showing strong outcomes for HIFU in prostate cancer treatment while enabling the majority of patients to delay or avoid surgery and radiation. As patients and physicians increasingly reconsider the tradeoffs of traditional surgery and radiation, these trends underscore a broader movement toward precision, outpatient care—positioning precision sound medicine at the forefront of the next era in prostate cancer treatment.

The details

Sonablate's FDA-cleared High-Intensity Focused Ultrasound (HIFU) platform enables physicians to precisely ablate prostate tissue without incisions, reducing the risk of incontinence and erectile dysfunction while delivering effective disease control. Backed by more than two decades of innovation and real-world clinical experience, Sonablate AI-Robotic HIFU has demonstrated strong outcomes across multiple studies, with metastasis-free survival and prostate cancer–specific survival reaching 100% at seven years, and high rates of maintaining urinary continence, avoiding new erectile dysfunction, and avoiding radical or systemic treatment.

  • Sonablate announced the key leadership appointments on April 9, 2026.

The players

Martin ('Marty') Wade

Has been appointed Chairman of the Board at Sonablate. He brings more than four decades of experience advising executive teams and boards on corporate strategy, capital markets, and transformational growth.

Brian Murrell

Has joined Sonablate as Chief Financial Officer. He adds nearly 30 years of finance and accounting experience, most recently as a Big Four accounting services partner, where he advised global public companies.

Yuki Ji

Serves as SVP, Global Strategy and Education, Chair of Culture and Community Committee (CCC) at Sonablate. She brings nearly two decades of medtech leadership experience spanning commercial strategy, physician education, and international market expansion.

Richard Yang

Is the CEO of Sonablate. He stated that 'Precision sound medicine represents a fundamental shift in how we treat disease—moving from invasive, one-size-fits-all approaches to targeted, patient-centric care.'

Sonablate Corp.

Is a global leader in non-invasive, focused ultrasound technologies and a pioneer in precision sound medicine. The company's Sonablate® HIFU system is FDA-cleared in the United States for prostate tissue ablation and has received regulatory approvals in more than 50 countries worldwide.

Got photos? Submit your photos here. ›

What they’re saying

“'Precision sound medicine represents a fundamental shift in how we treat disease—moving from invasive, one-size-fits-all approaches to targeted, patient-centric care. We believe this will define the future standard of care.'”

— Richard Yang, CEO of Sonablate

“'Having worked across diverse healthcare systems globally, it is clear that the future of medicine will be defined by treatments that balance efficacy with quality of life. Precision sound medicine has the potential to do exactly that—not only in prostate care, but across a wide range of diseases where non-invasive, targeted therapy can improve outcomes and reduce burden on patients and health systems.'”

— Yuki Ji, SVP, Global Strategy and Education, Chair of Culture and Community Committee (CCC) at Sonablate

“'At Sonablate, we believe leadership extends beyond technology to the culture we build and the communities we serve. Through advancing physician education, partnering with leading institutions, and championing access and equity—including for veterans—we are shaping a stronger ecosystem that benefits both patients and the future of healthcare.'”

— Yuki Ji, SVP, Global Strategy and Education, Chair of Culture and Community Committee (CCC) at Sonablate

What’s next

Sonablate's expanded leadership team will focus on accelerating global adoption, strengthening clinical integration, and expanding the company's precision sound medicine platform beyond prostate cancer and into additional therapeutic areas.

The takeaway

Sonablate's leadership expansion reflects the company's commitment to advancing precision sound medicine as a scalable, global platform that aligns with the broader shift toward outpatient care, value-based healthcare, and technologies that deliver better outcomes with fewer side effects. As demand for non-invasive, targeted therapies accelerates, Sonablate is positioning itself to lead the next wave of ultrasound-based therapeutics.